Payment overview · 2025
General Payments
$4,220.23
69 reported records · 29 companies
Healthcare provider profile · identity verified
Megha Shah
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · FLEMINGTON, NJ · NPI 1437393352
Verified facts
What the public records show
CMS Open Payments records show Megha Shah received $4,220.23 in general payments during 2025 across 69 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Erleada, Imbruvica, Libtayo, Venclexta, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Venclexta by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xtandi by this doctor in 2024.
Regeneron Healthcare Solutions, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LIBTAYO as an associated drug or biological on 22545 records involving 10925 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Libtayo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $2,107.07 | 49.9% | 6 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $1,152.74 | 27.3% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $105.57 | 2.5% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $84.83 | 2.0% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $72.72 | 1.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.72 | 1.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.23 | 1.3% | 3 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $52.78 | 1.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.93 | 1.2% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $40.03 | 0.9% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $36.89 | 0.9% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $35.78 | 0.8% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $33.80 | 0.8% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.54 | 0.8% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $23.98 | 0.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.81 | 0.6% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $21.94 | 0.5% | 1 | 2025 |
| MENARINI SILICON BIOSYSTEMS, INC. | Unresolved — no canonical attribution shown | $20.94 | 0.5% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.79 | 0.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.07 | 0.5% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $19.05 | 0.5% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $18.82 | 0.5% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.75 | 0.4% | 1 | 2025 |
| Fennec Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.65 | 0.4% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $18.16 | 0.4% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $17.22 | 0.4% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $16.89 | 0.4% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.85 | 0.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.68 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,950.00 | 2 |
| Food and Beverage | $1,198.83 | 63 |
| Education | $71.40 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $222.55 | 11 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $90.90 | 3 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $90.90 | 3 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $72.72 | 4 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $35.78 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Cellsearch Normalized: cellsearch |
Device | MENARINI SILICON BIOSYSTEMS, INC. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| VIVIMUSTA Normalized: vivimusta |
Drug | Azurity Pharmaceuticals, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Fyarro Normalized: fyarro |
Drug | Fennec Pharmaceuticals, Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Gamifant Normalized: gamifant |
Drug | SOBI, INC | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Syndax Pharmaceuticals, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| ALYMSYS Normalized: alymsys |
Drug | Amneal Pharmaceuticals LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ERLEADA erleada |
2025 | Erleada | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LIBTAYO libtayo |
2025 | Libtayo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Regeneron Healthcare Solutions, Inc. Exact reporting entity; no affiliate inference |
2025 | LIBTAYO open payments reported associated product |
CMS Open Payments — General Payments 22545 supporting records · 10925 recipient NPIs · example record 1212855234 |
Libtayo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 485 | 141 |
| Raloxifene Hcl | Raloxifene Hcl | 76 | 25 |
| Letrozole | Letrozole | 70 | 22 |
| Procrit | Epoetin Alfa | 41 | 17 |
| Eliquis | Apixaban | 40 | suppressed |
| Cinvanti | Aprepitant | 38 | suppressed |
| Lupron Depot | Leuprolide Acetate | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 12 |
| Hydroxyurea | Hydroxyurea | 28 | suppressed |
| Verzenio | Abemaciclib | 28 | suppressed |
| Venclexta | Venetoclax | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Imbruvica | Ibrutinib | 25 | suppressed |
| Neulasta | Pegfilgrastim | 24 | suppressed |
| Revlimid | Lenalidomide | 23 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Neulasta Onpro | Pegfilgrastim | 18 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Exemestane | Exemestane | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Azacitidine | Azacitidine | 15 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 15 | suppressed |
| Lenvima | Lenvatinib Mesylate | 15 | suppressed |
| Ruxience | Rituximab-Pvvr | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 14 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 13 | suppressed |
| Darzalex Faspro | Daratumumab-Hyaluronidase-Fihj | 13 | suppressed |
| Erleada | Apalutamide | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Libtayo | Cemiplimab-Rwlc | 11 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Xtandi | Enzalutamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,220.23 · 69 records | AstraZeneca Pharmaceuticals LP | ALYMSYS, AYVAKIT, BLENREP, BRUKINSA, Cellsearch, DANZITEN, DATROWAY, EMRELIS, ENHERTU, EPKINLY, ERLEADA, Fyarro, GOMEKLI, Gamifant, IBRANCE, IMBRUVICA, INJECTAFER, JEMPERLI, KISQALI, LIBTAYO, LYNPARZA, MONJUVI, NIKTIMVO, NINLARO, OGSIVEO, OJJAARA, OPDUALAG, ORGOVYX, Onivyde, Orserdu, PEMAZYRE, PLUVICTO, PYRUKYND, REBLOZYL, RYTELO, SARCLISA, TALZENNA, TUKYSA, Trodelvy, VENCLEXTA, VIVIMUSTA, Vonjo, XPOVIO, XTANDI, ZEJULA, clonoSEQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Erleada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error